Overview

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Status:
Completed
Trial end date:
2021-03-19
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to characterize and compare the pharmacokinetic profiles of mitapivat following a single dose administration of 100 mg mitapivat in two tablet formulations (50 mg and 100 mg tablet strengths) in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.